MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in …

Feb 28, 2018 · AstraZeneca today announced that its global biologics research and development arm, MedImmune, is spinning out six molecules from its early-stage inflammation and …

Feb 14, 2019 · After 30 years of drug development, MedImmune will cease to exist as an industry name now that owner AstraZeneca has decided to retire the brand as part of ongoing …

MedImmune’s novel ADC candidate employs the PBD payload and demonstrates early efficacy against cancer . Indication . Candidate • Novel ADC conjugated with PBD payload • Tumor …

MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular, Renal and Metabolic Diseases, and Infection and Vaccines.

Dec 1, 2008 · MedImmune, Inc. manufactures, markets and/or distributes more than 3 drugs in the U.S.

Manufacturer: MedImmune, LLC Indications: For active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the …

Building on our long-standing heritage in this field from Cambridge Antibody Technology (CAT) and MedImmune, we harness our extensive antibody discovery and protein engineering …

Mavrilimumab was discovered as CAM-3001 by Cambridge Antibody Technology and is being developed by MedImmune, Inc. [1] as an investigational drug for the treatment of rheumatoid …

Mar 8, 2025 · MedImmune, the R&D arm of AstraZeneca has teamed up with California based 4DMT, a next-generation virus-based gene therapy research house developing a treatment for …